Skip to main content
Premium Trial:

Request an Annual Quote

Proteome Sciences Inks $2M Deal with Genting TauRx for Alzheimer's Biomarker Work

NEW YORK (GenomeWeb) – Proteome Sciences said today that it has signed a $2 million contract with Genting TauRx Diagnostic Centre, an affiliate of TauRx Therapeutics, to provide protein biomarker work in support of the company's Phase III trial of its Alzheimer's drug LMTX.

Proteome Sciences will analyze blood samples from patients enrolled in the trial and from age-matched controls with the aim of building protein panels for the detection of Alzheimer's and for monitoring treatment efficacy.

Under the terms of the deal, Proteome Sciences will receive $2 million in research fees comprising upfront and milestone payments, while GTD will receive a license to the company's existing blood biomarker for Alzheimer's. The firms will share commercialization rights to any diagnostic assays developed.

Proteome Sciences currently offers a panel of nine plasma proteins for Alzheimer's research including patient stratification in clinical trials.

LMTX is being developed by TauRx Therapeutics for the treatment for Alzheimer’s of mild to moderate severity by targeting the tau pathway.

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.